Basement Membrane Derived Fibulin-1 and Fibulin-5 Function as Angiogenesis Inhibitors and Suppress Tumor Growth

The fibulins are a family of secreted glycoproteins that are characterized by repeated epidermal-growth-factor–like domains and a unique C-terminus structure. Fibulins modulate cell morphology, growth, adhesion, and motility. Our initial basement membrane degradome screen using Cathepsin D, a tumor microenvironment–associated protease, contained fragments of fibulin-1 and full length fibulin-5. In this report, we evaluate the antiangiogenic activity of fibulin-1 and fibulin-5. Tumor studies demonstrate that both fibulin-1 and fibulin-5 suppress HT1080 tumor growth. CD31 labeling and TUNEL assay further reveal that fibulin-1 suppression of HT1080 tumor growth is associated with diminished angiogenesis and also enhanced apoptosis of endothelial cells and tumor cells. In contrast, fibulin-5 inhibits tumor angiogenesis with a minimal anti-apoptotic affect. Cathepsin D digestion of fibulin-1 produces a fragment with nearly the same molecular weight as fibulin-5, and this fragment (named Neostatin) inhibits endothelial cell proliferation. Additionally, degradation of basement membrane by cathepsin D liberates both fibulin-1 fragments and fibulin-5, which function to inhibit angiogenesis.

[1]  V. Laurent-Matha,et al.  Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.

[2]  W. Schiemann,et al.  Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. , 2006, Cancer research.

[3]  W. Schiemann,et al.  Fibulin-5 function during tumorigenesis. , 2005, Future oncology.

[4]  W. Gallagher,et al.  Fibulins and cancer: friend or foe? , 2005, Trends in molecular medicine.

[5]  R. Kalluri,et al.  Endogenous inhibitors of angiogenesis. , 2005, Cancer research.

[6]  N. Katunuma,et al.  Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. , 2005, The journal of medical investigation : JMI.

[7]  W. Schiemann,et al.  Fibulin-5 promotes wound healing in vivo. , 2004, Journal of the American College of Surgeons.

[8]  W. Schiemann,et al.  Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. , 2004, DNA and cell biology.

[9]  S. Ménard,et al.  Immunological and pathobiological roles of fibulin-1 in breast cancer , 2004, Oncogene.

[10]  G. Hortobagyi,et al.  Prognostic molecular markers in early breast cancer , 2004, Breast Cancer Research.

[11]  L. Greene,et al.  Fibulins: physiological and disease perspectives , 2003, EMBO reports.

[12]  R. Timpl,et al.  Fibulins: a versatile family of extracellular matrix proteins , 2003, Nature Reviews Molecular Cell Biology.

[13]  M. Duffy,et al.  Elevated expression and altered processing of fibulin-1 protein in human breast cancer , 2003, British Journal of Cancer.

[14]  Christoph Peters,et al.  Toward Computer-Based Cleavage Site Prediction of Cysteine Endopeptidases , 2003, Biological chemistry.

[15]  Masashi Yanagisawa,et al.  Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo , 2002, Nature.

[16]  Tasuku Honjo,et al.  Fibulin-5/DANCE is essential for elastogenesis in vivo , 2002, Nature.

[17]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[18]  P. Laurent-Puig,et al.  Human fibulin‐4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues , 2001, FEBS letters.

[19]  R. Timpl,et al.  Fibulin-1 Is a Ligand for the C-type Lectin Domains of Aggrecan and Versican* , 1999, The Journal of Biological Chemistry.

[20]  P. Pujol,et al.  Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. , 1998, The American journal of pathology.

[21]  H. Rochefort,et al.  Estradiol and fibulin‐1 inhibit motility of human ovarian‐ and breast‐cancer cells induced by fibronectin , 1998, International journal of cancer.

[22]  H. Rammensee,et al.  Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. , 1997, European journal of biochemistry.

[23]  T. Sasaki,et al.  Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. , 1996, Experimental cell research.

[24]  M. Somerman,et al.  Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure , 1990, The Journal of cell biology.

[25]  E. Ruoslahti,et al.  Fibulin, a novel protein that interacts with the fibronectin receptor β subunit cytoplasmic domain , 1989, Cell.

[26]  R. Kalluri.  Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. , 2002, Cold Spring Harbor symposia on quantitative biology.